Centessa Pharmaceuticals (CNTA) Return on Sales (2025)

Centessa Pharmaceuticals (CNTA) reported Return on Sales of 0.13% for Q4 2025, up 18.61% on a QoQ basis from 0.16% in Q3 2025.

Centessa Pharmaceuticals (CNTA) has 1 years of Return on Sales data on file, last reported at 0.13% in Q4 2025.

  • Quarterly Return on Sales changed N/A year-over-year to 0.13% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.13% (changed N/A YoY) and the FY2025 annual result came in at 0.13%, changed N/A from the prior year.
  • Return on Sales rose to 0.13% in Q4 2025 per CNTA's latest filing, from 0.16% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.02% in Q1 2025 and bottomed at 0.16% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.00%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.00%
7 Evaxion A 62.56 Bn 62.54 Bn - 0.00%
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.00%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.00%
10 Centessa Pharmaceuticals 6.12 Bn 6.12 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -0.13%
Sep 30, 2025 -0.16%
Jun 30, 2025 -0.15%
Mar 31, 2025 -0.02%